FDA’s Idea Lab Seeks to Reimagine Device Use in the Home Through New Virtual Reality Prototype

January 2, 2025

Reading Time : 1 min

On December 30, 2024, FDA unveiled an Idea Lab as part of its Home as a Health Care Hub initiative to reimagine how new and existing medical devices can be incorporated in a home environment.

As previously discussed here, FDA created the Home as a Health Care Hub to advance health equity across the United States. In April 2024, the agency began working on an Idea Lab to help developers design new solutions, visualize how their medical devices can integrate into people’s homes and daily lives, and ensure compatibility with other health technologies. FDA chose people living with diabetes as its first test case.

The Idea Lab features Lilypad™, a virtual reality prototype, designed to immerse users into various affordable housing environments of people living with diabetes—a chronic condition impacting millions of Americans. Available online, Lilypad™ offers a realistic view into the challenges and barriers these individuals face in managing their condition. The software will allow users to visualize and create integrative solutions, innovate new home use devices and adapt existing devices to better meet patient needs in the home environment.

In addition to Lilypad™, the Idea Lab provides insights from patients, caregivers, providers, and experts and landscape research on different design opportunities with the goal of helping FDA, innovators and other stakeholders better understand how current medical devices operate in people’s homes and daily lives. On the Idea Lab’s web page, interested parties can explore fictional patient personas, the Lilypad™ virtual reality (VR) experience, key questions and considerations for innovators, and research and insights.

Numerous companies are already exploring VR as a means of demonstrating at-home and point of care use cases for their medical technologies. FDA’s Idea Lab provides an additional opportunity to explore opportunities for at-home uses with FDA.

Share This Insight

Previous Entries

Eye on FDA

February 24, 2026

On February 23, 2026, the Food and Drug Administration (FDA) released a draft guidance entitled “Considerations for the Use of the Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic Conditions with Known Biological Cause.” This guidance is designed for targeted, individualized therapies for which randomized controlled trials are not practical due to a small patient population, and was previewed by the Commissioner in several public forums.

...

Read More

Eye on FDA

February 17, 2026

On February 3, 2026, the Consolidated Appropriations Act, 2026 (P.L. 119-75) became law and marked an important milestone in the bipartisan congressional effort to reauthorize the rare pediatric disease priority review voucher program. Section 6604 of this law extends the Food and Drug Administration’s (FDA) authority to issue priority review vouchers to encourage treatments for rare pediatric diseases through September 30, 2029.

...

Read More

Eye on FDA

February 17, 2026

In case you missed it, Department of Health and Human Services Secretary Robert F. Kennedy Jr. and former Food and Drug Administration (FDA) Commissioner David Kessler appeared on 60 Minutes this past Saturday, February 15, in a segment titled “Generally Recognized as Safe.” As the title suggests, the conversation centered on FDA’s Generally Recognized as Safe (GRAS) regulatory pathway (for background, see our prior post discussing in more detail the GRAS process), as well as Commissioner Kessler’s August 2025 citizen petition urging FDA to revoke the GRAS status of refined carbohydrates used in industrial food processing (discussed in more detail in our earlier coverage of the petition).

...

Read More

Eye on FDA

February 3, 2026

On February 1, 2026, the Food and Drug Administration (FDA) officially started accepting requests to participate in the FDA PreCheck pilot program. The goal of the program is to strengthen the domestic pharmaceutical supply chain by making the review and inspection process more predictable for U.S.-based drug manufacturing facilities.

...

Read More

© 2026 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.